// App-Quantinova.ai

: A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

Researchers

Presenter

  • R Donald Harvey

Principal Investigators

  • Joseph K Franz

  • Nisha S. Joseph

  • Jonathan L. Kaufman

  • Elise Hitron

  • Hannah Collins

  • Catherine Braga

  • Ludimila Cavalcante

  • Kathryn T. Maples

  • Craig C Hofmeister

  • Madhav Dhodapkar

  • Sagar Lonial

  • Ajay K. Nooka

Medical Centers

  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Louisville, KY

  • IUPMC, Pittsburgh, PA

  • Department of Pharmacy, Winship Cancer Institute of Emory University, Atlanta, GA

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Renal insufficiency

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Tolerability

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved